The authors report a clinical study of the efficacy of a butyrophenone derivative (haloperidol) in a sample of mentally retarded children with associated emotional disturbances. The drug was noted to significantly alter the major target symptoms of such emotional disturbances. It appears that haloperidol is a welcome addition to the slowly growing armamentarium of effective psychopharmacological agents for the emotionally disturbed mentally retarded.
No takes yet. Share an insight, caveat, or question.
Burk et al. (1968) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: